MBII Marrone Bio Innovations Inc

Marrone Bio Innovations addresses increasing threats to almonds with two biological insecticides

Marrone Bio Innovations addresses increasing threats to almonds with two biological insecticides

Venerate® XC and Grandevo® WDG are proven to minimize damage from navel orangeworm and other pests, driving improved crop yields and quality while empowering growers to meet California’s Almond Orchard 2025 Goals

DAVIS, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- As the global market demand for almonds continues to increase exponentially, one of the greatest threats to crops is navel orangeworm, Amyelois transitella.

According to a 2018 study by Sacramento-based Blue Diamond Growers, Almond growers are at risk of losing 20 percent of their crop due to this increasingly common pest, which causes an  estimated revenue loss to the farmer of $1,700 per acre.

The addition of a bioinsecticide from (NASDAQ: MBII) (MBI), a leading developer of biological crop protection and plant health solutions – to the May and hull split conventional spray programs decreased total nut damage by an additional two percent in extensive 2018 field trials. The addition of Venerate® XC delivered a six-to-one return on investment for growers, while multiple trials show that Venerate® XC added to a conventional spray program improved total performance by 33 percent based on damage reduction and number of eggs and pests present.

“It could be a heavy year for navel orangeworm populations because orchard sanitation or mummy removal has been a particular challenge this winter,” explained Kevin Hammill, Chief Commercial Officer of Marrone Bio. “This pest  can cost growers hundreds to thousands of dollars per acre because it causes direct damage to the nut and may be an issue in international markets due to aflatoxin concerns. Navel orangeworm has developed resistance to some commonly used chemicals such as pyrethroids. The addition of Venerate® XC,  with its unique mode of action, reduces resistance development to standard conventional spray programs and minimizes the damage caused by the navel orangeworm, offering higher-quality crop.”

In addition, peach twig borer and two-spotted spider mite also pose threats to almond crops. A rotation of MBI’s Grandevo® WDG bioinsecticide sprayed at bloom significantly enhances control of these pests, while still protecting beneficial insects. The rotational benefit of Grandevo® WDG and Venerate® XC demonstrates increased control of peach twig borer and two-spotted spider mite as a secondary benefit to navel orangeworm treatments.

Both Venerate® XC and Grandevo® WDG support objectives of the from the Almond Board of California –which is dedicated to producing an economically, environmentally and socially responsible crop for California – more specifically, the commitment to increase adoption of environmentally friendly pest management tools by 25 percent.

For more information on Venerate® XC and Grandevo® WDG, please contact your local Marrone Bio Innovations certified distributor or visit

About Marrone Bio Innovations

Marrone Bio Innovations Inc. (NASDAQ: MBII) strives to lead the movement to more a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that support a better tomorrow for farmers, turf managers and consumers around the globe. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies to rapidly develop seven effective and environmentally responsible pest management active ingredients and nine products to help customers operate more sustainably while uniquely improving plant health and increasing crop yields. Supported by a robust portfolio of over 400 issued and pending patents around its superior natural product chemistry, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo® WDG, Grandevo® CG, Venerate® XC, Venerate® CG, Majestene®, Haven® and Amplitude®, Zelto® and Zequanox®.

Learn more about Marrone Bio Innovations at . Follow us on social media: , and .

Marrone Bio Innovations Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, including examples regarding the potential of and market for MBI’s Grandevo and Venerate products and their use and value to growers should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include the potential of the MBI’s products and market projections. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including weather, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.

Press Inquiries                 

Jay Austin



914-980-7788

MBI Investor Relations                

Greg Falesnik                                    

Managing Director          

MZ Group – MZ North America

949-385-6449                                    

                         

Commercial Agriculture & Turf Public Relations

Alicia Gillman

Agriculture & Turf Trade Media



480-889-4219

EN
18/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Marrone Bio Innovations Inc

 PRESS RELEASE

Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement wi...

Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp. RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI’s stockholde...

 PRESS RELEASE

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Res...

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include: Higher sales of row crop products in the first quarter were somewhat offset by lower sales into specialty crop markets, which were affected by adverse weather conditions. Based on the strength of current orders, revenues in the first half are expected to increase in the ...

 PRESS RELEASE

Marrone Bio Innovations to Report First Quarter 2022 Results on Wednes...

Marrone Bio Innovations to Report First Quarter 2022 Results on Wednesday, May 11 at 4:30 p.m. Eastern Time RALEIGH, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the first quarter ended March 31, 2022, after market close on Wednesday, May 11, 2022. Management will host an investor conference call at 4:30 p.m. ET to discuss Marrone Bio Innovations’ first quarter financial re...

 PRESS RELEASE

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 202...

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include: Full year revenues rose 15.5%, with a 40.2% increase in the fourth quarter.Gross profit grew 19.1% and 31.5% for the full year and fourth quarter, respectively, with margins exceeding 59% in both periods.For the full year, net loss was ...

 PRESS RELEASE

Marrone Bio Expands Biological Seed Treatment Collaboration for Row Cr...

Marrone Bio Expands Biological Seed Treatment Collaboration for Row Crops Company poised for continued growth in a $6+ billion market¹ RALEIGH, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MBII), has signed an agreement with Corteva Agriscience (NYSE: CTVA) that expands the opportunity for MBI technologies to be used on seeds sold by Corteva for row crops globally. Marrone Bio currently provides seed treatment solutions to Corteva for use throughout Europe. MBI introduced biological seed treatments as a sustainable alternative to control yield-robbing pests in the United States i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch